ArQule, Inc. (NASDAQ:ARQL)

CAPS Rating: 2 out of 5

A clinical-stage biotechnology company, engaged in the research and development of cancer therapeutics. Its mission is to research, develop and commercialize targeted cancer drugs with reduced toxicities compared to conventional cancer chemotherapeutics.

Recs

0
Player Avatar hiddenflem (77.70) Submitted: 12/3/2010 10:26:48 AM : Outperform Start Price: $5.55 ARQL Score: -2.24

Hoping the market notices ARQL is well positioned to possibly ride on the coat-tails of Exel's drug XL184...

Featured Broker Partners


Advertisement